631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform

631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform

Bibliographic Details
Main Authors: Dahea Lee, Donggeon Kim, Soomin Ryu, Byoung Chul Lee
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-b8bdb937f28742a8ba76c9e8ec77c79a
record_format Article
spelling doaj-b8bdb937f28742a8ba76c9e8ec77c79a2020-12-11T10:03:06ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0631631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platformDahea Lee0Donggeon Kim1Soomin Ryu2Byoung Chul Lee3Kanaph Therapeutics, Seoul, Korea, Republic ofKanaph Therapeutics, Seoul, Korea, Republic ofKanaph Therapeutics, Seoul, Korea, Republic ofKanaph Therapeutics, Seoul, Korea, Republic of
collection DOAJ
language English
format Article
sources DOAJ
author Dahea Lee
Donggeon Kim
Soomin Ryu
Byoung Chul Lee
spellingShingle Dahea Lee
Donggeon Kim
Soomin Ryu
Byoung Chul Lee
631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
Journal for ImmunoTherapy of Cancer
author_facet Dahea Lee
Donggeon Kim
Soomin Ryu
Byoung Chul Lee
author_sort Dahea Lee
title 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
title_short 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
title_full 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
title_fullStr 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
title_full_unstemmed 631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform
title_sort 631 development of highly efficacious and safe targeted cancer immunotherapy via il12-based tmekine™ platform
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT dahealee 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform
AT donggeonkim 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform
AT soominryu 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform
AT byoungchullee 631developmentofhighlyefficaciousandsafetargetedcancerimmunotherapyviail12basedtmekineplatform
_version_ 1724386596860461056

Similar Items